HPV Integration Testing for Human Papillomavirus-Positive Women

Last updated: June 24, 2017
Sponsor: Huazhong University of Science and Technology
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cervical Cancer

Pelvic Cancer

Dysfunctional Uterine Bleeding

Treatment

N/A

Clinical Study ID

NCT02576262
CCS-02
  • Ages 30-65
  • Female
  • Accepts Healthy Volunteers

Study Summary

Papanicolaou (Pap) triage, with high specificity, has been recommended for primary Human papillomavirus (HPV) testing but is flawed by poor sensitivity and cytologist dependence. the investigators evaluated the potential role of HPV Integration detection in cervical exfoliated cells in HPV-positive women from a clinic-based population.

Eligibility Criteria

Inclusion

Inclusion Criteria: Women aged 30-65 years old visiting the gynecologic clinic of hospital

Exclusion

Exclusion Criteria:

  1. Not providing informed consent

  2. previously confirmed CIN, cervical cancer, or other malignancies

  3. previous therapeutic procedure to cervix

  4. pregnancy

Study Design

Total Participants: 1200
Study Start date:
September 01, 2015
Estimated Completion Date:
September 30, 2020

Connect with a study center

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei 430030
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.